Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Genexine/I-Mab Announce Positive Results from Phase III Growth Hormone Trial

publication date: Aug 31, 2023

Genexine, a South Korean biotech, announced its long-acting growth hormone met the primary endpoint in a China Phase III trial conducted by Shanghai’s I-Mab, which in-licensed China rights to the drug, eftansomatropin alfa. Genexine said GX-H9 proved non-inferiority in growth measures to Norditropin® in children with growth hormone deficiency, but the candidate offers a much improved dosing schedule of once-per-week compared to Norditropin’s daily dosage. The trial measured growth at the 52-week mark, finding both drugs produced around 10.5 cm/year. More details....

Stock Symbol: (KOSDAQ:095700)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital